Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other serious diseases, particularly those of high unmet medical need, with a vision to improve patient healthcare with orally available innovative medicines. The Company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.